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Autoimmunity refers to an inappropri-
ate immune response against self-compo-
nents of the host that results in patholog-
ical conditions. Autoimmune diseases are
characterized by an activation of autore-
active T and B cells, are associated in
some cases with the production of patho-
genic autoantibodies against self-mole-
cules, culminating in inflammation and
tissue damage. The reasons for the break-
down of tolerance mechanisms leading to
autoimmunity are not clearly known.
However, a combination of genetic, im-
munological, and environmental factors
plays a critical role in the pathogenesis of
autoimmunity [1–5].
Autoimmunity Can Predispose
to Infectious Diseases
During the course of autoimmunity,
autoantibodies that can neutralize key
components of the immune system that
are essential in mounting anti-microbial
responses may be produced (Figure 1).
These autoantibodies might either exacer-
bate ongoing infectious diseases or predis-
pose the individual to an increased risk of
bacterial, viral, and opportunistic fungal
infections. For example, cytokines play a
critical role in the process of mounting
anti-microbial responses due to their
ability to regulate the innate and adaptive
immune systems, in polarizing T cell
responses, and by acting as effector
molecules. Thus, IL-12 mediates Th1 cell
differentiation and IL-4 influences Th2
differentiation. IL-6, IL-21, TGF-b, IL-1b,
and IL-23 are critical for the differentia-
tion and expansion of Th17 cells. Th1 cells
produce cytokines IFN-c and IL-2, and
confer protection against intracellular
pathogens (viruses and intracellular bacte-
ria such as Mycobacterium and Salmonella).
Th2 cells produce IL-4, IL-5, and IL-13,
and are important to clear extracellular
pathogens and parasites. Th-17 cells
secrete IL-17, IL-21, and IL-22, and
provide protection against several extra-
cellular pathogens, including fungi such as
Candida (Figure 1) [6–9]. In addition, type I
IFNs have a critical role in anti-viral
immunity and in modulating T and B cell
responses. Therefore, it can be conceived
that the development of neutralizing
antibodies against any of these cytokines
as a consequence of autoimmunity affects
the cellular functions and clearance of
pathogens and predisposes the host to
infectious diseases. This is further support-
ed by reports of a high prevalence of
infections in autoimmune patients treated
with neutralizing monoclonal antibodies to
inflammatory cytokines. Patients with
rheumatoid arthritis, Crohn’s disease, or
psoriasis treated on a chronic basis with
monoclonal antibodies to TNF-a are
predisposed to mycobacterial, listerial,
and viral infections [10–12].
Specific Examples of
Autoimmunity Favoring
Infectious Diseases
Several reports have now demonstrated
the occurrence of neutralizing autoanti-
bodies against cytokines in patients with
infections. These reports thus provide a
pointer towards a previously unknown link
between autoimmune responses and pre-
disposition to infectious diseases.
A correlation between neutralizing au-
toantibodies to IFN-c and mycobacterial
infections has been reported [13–20].
Moreover, the clinical features of patients
with anti-IFN-c immunoglobulin G (IgG)
are analogous to those with genetic defects
in the IFN-c/IL-12 pathway, which is
characterized by progressive or dissemi-
nated infection with mycobacteria of low
virulence, indicating that anti-IFN-c IgG
induces an acquired immunodeficiency
state and predisposes to mycobacterial
infections [13–20]. These anti-IFN-c IgG
neutralized IFN-c in whole blood culture,
inhibited IFN-c-dependent phosphoryla-
tion of STAT-1 and production of TNF-a
and IL-12 by normal peripheral blood
mononuclear cells (PBMCs) and macro-
phages, and inhibited HLA-DR expres-
sion in normal monocytes [14–17]. In
another study, one patient’s serum was
shown to inhibit IFN-c-mediated upregu-
lation of MHC class I on Jurkat cells [20].
Given the critical role of the type I
cytokine pathway in the immune response
to mycobacterial infections [21], these
reports provide direct evidence for how
anti-IFN-c autoantibodies can affect pro-
tective anti-mycobacterial immunity.
Recurrent staphylococcal cellulitis and
subcutaneous abscesses were reported in a
child with autoantibodies against IL-6
[22]. These anti-IL-6 autoantibodies in-
hibited IL-6-mediated STAT3 phosphor-
ylation and C-reactive protein (CRP)
production in Hep3B cells. Since IL-6 is
pivotal for CRP induction, these results
indicated that anti-IL-6 autoantibodies
contributed to the lack of CRP response
in this patient during staphylococcal
infections. In addition, IL-6- deficient
mice have been shown to be susceptible
to various pyogenic infections, including
Streptococcus pneumoniae, Pseudomonas aerugi-
nosa, and Klebsiella pneumoniae [23–26].
Interestingly, autoantibodies to IL-6 were
not identified in other patients with severe
staphylococcal diseases and hence suggest
that anti-IL-6 autoantibodies were not
generated due to molecular mimicry with
Staphylococcus aureus. In addition, the course
of clinical events in the patient was
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autoantibodies that preceded staphylococ-
cal infection.
Patients suffering from pulmonary al-
veolar proteinosis (PAP) present with
neutralizing antibodies against granulo-
cyte/macrophage colony–stimulating fac-
tor (GM-CSF) and show high mortality
due to infection [27]. GM-CSF has a key
role in enhancing the antimicrobial activ-
ities of neutrophils and macrophages by
augmenting the expression of CD11b, an
adhesion molecule that mediates neutro-
phil adhesion to endothelial cells, and
hence promoting the recruitment of
neutrophils to the site of infection;
promoting the differentiation of macro-
phages and dendritic cells (DCs); and by
priming the phagocytosis and bactericidal
activities of these cells. Low levels of GM-
CSF autoantibodies are present in healthy
individuals. These autoantibodies are
implicated in scavenging and neutralizing
free GM-CSF and to regulate myeloid cell
functions and GM-CSF-mediated inflam-
mation and autoimmunity [28]. However,
active PAP patients have high amounts of
GM-CSF autoantibodies that impair the
antimicrobial functions of neutrophils,
macrophages, and the expression of
CD11b [29]. In addition, these autoanti-
bodies exist abundantly in the lungs, and
by effectively blocking GM-CSF binding
to its receptor, they specifically inhibit
alveolar macrophage differentiation,
phagocytosis, and surfactant catabolism
[30,31]. Patient-derived GM-CSF auto-
antibodies reproduced PAP in experimen-
tal non-human primate and murine
models [29,32], while individuals with
mutations in GM-CSF receptor are also
affected with PAP [33]. These results thus
confirm the causal relationship between
defective GM-CSF function, autoantibod-
ies, and PAP.
Th17 cytokines are implicated in pro-
tection against fungal infections, including
Candida at mucosal surfaces, and hence
neutralizing antibodies to Th17 cytokines
can predispose to fungal infections
[8,34,35]. Interestingly, neutralizing auto-
antibodies against Th17 cell cytokines IL-
17A, IL-17F, and IL-22 have been report-
ed in chronic mucocutaneous candidiasis
(CMC) patients with autoimmune poly-
endocrinopathy syndrome-1 (APS-1) or
thymoma [36,37]. Of particular impor-
tance, the autoantibody titers were high
before the onset of CMC. Further, indi-
viduals with mutations in STAT3 and IL-
12RB1 showed impaired development of
Th17 cells and higher susceptibility to
candidiasis [38].
Figure 1. Host immune response to pathogens and predisposition to infections due to autoimmunity. Antigens from invading
pathogens are recognized and presented by innate immune cells (A) such as macrophages and dendritic cells to CD4+ and CD8+ T cells (CTL) (B).
CD8+ T cells recognize endogenous antigens presented by MHC class I molecules and exert cytotoxic functions upon activation. CD4+ T cells
recognize antigens presented in the context of MHC class II molecules, and under the influence of innate cells and cytokine milieu, CD4+ T cells can
be polarized into different subsets such as Th1, Th2, Th17, and regulatory T cells (Tregs) that secrete distinct cytokines. CD4+ T cells provide help to B
cells to produce antigen-specific antibodies (C). However, due to autoimmunity, neutralizing autoantibodies can be produced against any of these
key components of the immune system critical for mounting anti-microbial responses and might either predispose to an increased risk of bacterial,
viral, and opportunistic fungal infections or exacerbate the ongoing infectious diseases. Indeed, in patients with infections, the occurrence of
neutralizing autoantibodies against several key cytokines such as IFN-c, IL-6, GM-CSF, IL-17, and IL-22 (highlighted in red boxes) that interfere with the
host immune response to pathogens have been demonstrated. In addition, autoantibodies are also reported against type I IFNs and IL-12 that might
play role in predisposition to infections (highlighted in blue boxes). CTLA-4, cytotoxic T lymphocyte antigen-4; CTL, cytotoxic T lymphocyte; FasL, Fas
ligand; GM-CSF, granulocyte/macrophage–colony stimulating factor.
doi:10.1371/journal.ppat.1001077.g001
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autoantibodies to type I IFNs (such as
IFN-a2, IFN-v), IL-12, and TNF-a were
also identified in patients with autoim-
mune and rheumatic diseases and in those
with chronic infections [39]. Intractable
(even fatal) infections in myasthenia gravis
patients with thymoma might be related to
high titers of anti-IL-12 and anti-IFNa
autoantibodies that can reduce an IFN-c
response with a bias towards an IL-4
response [40].
Taken together, anti-cytokine autoanti-
bodies induce an acquired immune-com-
promised state that predisposes the host to
infections. Although autoantibodies to
several cytokines are relatively widespread,
they rarely neutralize to a significant
extent [39]. Further, anti-cytokine auto-
antibodies do not seem to have co-
distribution, and cytokines do have redun-
dant functions; hence, severe infections are
not common unless as described above,
and neutralizing autoantibodies are devel-
oped against specific cytokines that are key
in an anti-microbial response.
In view of these findings, we suggest that
patients with uncontrolled or repeated
infections despite antimicrobial therapy
should be considered for screening and
evaluating autoimmunity. Although re-
ported examples are of autoantibodies to
cytokines, the occurrence of autoantibod-
ies that target either molecules implicated
in the recognition of pathogens (such as
Toll-like receptors and lectin receptors) or
antigen presenting and co-stimulatory
molecules cannot be ruled out. Indeed,
genetic defects or polymorphisms in pat-
tern recognition receptors and their sig-
naling pathways and susceptibility to
infections have been reported [41–44].
Enigma of Induction of Anti-
Cytokine Autoantibodies
Despite the reports of anti-cytokine
antibodies in several malignant or infec-
tious diseases and their low titers in
healthy individuals, the high titers are
predominant in autoimmune diseases [39].
Consensually, anti-cytokine antibodies
against type I IFNs, IL-12, IL-17, and
IL-22 are found in APS-1 or myasthenia
gravis patients associated with or without
thymoma [36,37,45]. Here, AIRE (auto-
immune regulator), a novel gene that
regulates peripheral self-antigen expres-
sion in medullary thymic epithelia and
DCs, is mutated, leading to disturbed self-
tolerance mechanisms. Thus, APS-1 pa-
tients may display autoantibodies against
type I IFNs and IL-17 cytokines as a result
of impaired AIRE-dependent tolerance
induction. Further, extensive work by the
Meager and Willcox group provided clues
toward autoimmunizing mechanisms and
innate cells (plasmacytoid and myeloid
DCs) in the induction of anti-cytokine
antibodies to type I IFNs and IL-12
[39,40,45].
Therefore, it is probable that autoanti-
bodies are produced as a consequence of
infections and these autoantibodies subse-
quently exacerbate the infectious diseases
or, alternatively, a cryptic autoimmunity
develops due to unknown reasons that
predispose the individual to infections.
Infectious agents and vaccines are often
thought to be one of the environmental
factors that induce autoimmunity either by
molecular mimicry, epitope spreading,
bystander activation of immune system,
or polyclonal activation of immune cells
[2,3]. It is thus likely that in case of chronic
persistent diseases such as tuberculosis, a
pathogen might trigger the autoimmune
process by one of these mechanisms.
Indeed, the majority of patients with
autoantibodies and mycobacterial infec-
tions originated from disease-endemic
areas [13–20]. Therefore, dissection of
underlying causes of autoimmunity such as
genetic polymorphisms, gene deficiency,
or environmental factors might shed light
on these unanswered questions.
Therapeutic Options for
Autoimmunity-Associated
Infectious Diseases
Therapeutic strategies for autoimmuni-
ty-associated infectious diseases should be
aimed at controlling the infection as well
as inhibiting the autoimmune response:
blocking autoantibody-producing B cells
and neutralizing autoantibodies. In this
context, a combination of anti-microbial
agents and immunosuppressive treatments
represents a classical line of therapy for
autoimmunity-associated infectious diseas-
es. Plasmapheresis that removes autoanti-
bodies or supplementing exogenous cyto-
kines (against which autoantibodies have
developed) are other potential therapeutic
strategies. However, such therapeutic
strategies do not eliminate the source of
autoantibodies, i.e., autoantibody-produc-
ing B cells and plasma cells.
Autoantibody-producing B cells can be
eliminated by B cell–targeted therapies
(such as monoclonal antibodies to CD20,
CD19, and CD22 or to B cell-activating
factor (BAFF) [46–48]). However, repeat-
ed cycles of B cell–targeted therapies can
lead to a reduction in total immunoglob-
ulin level and predisposition to serious
infections [49,50]. Also, these therapeutic
agents do not target antibody-producing
plasma cells.
In view of proven safety and efficacy in
diverse autoimmune diseases, polyclonal
intravenous immunoglobulin (IVIg) in
combination with anti-microbial agents
represents an attractive therapy for auto-
immunity-associated infections [51]. IVIg
targets both cellular and soluble media-
tors of autoimmunity and inhibits the
disease by multi-pronged mutually non-
exclusive mechanisms such as neutraliza-
tion of anti-cytokine autoantibodies by
broad-spectrum anti-idiotypic antibodies,
induction of B cell tolerance, inhibition of
cellular proliferation, regulation of immu-
noglobulin repertoire, suppression of in-
nate antigen presenting cells and inhibi-
tion of T cell help to B cells, and
expansion of CD4+CD25+ regulatory T
cells, the cells that are critical for
maintaining immune tolerance and to
suppress autoimmunity [51,52]. Since
IVIg is obtained from pooled plasma of
several thousand healthy blood donors,
based on the exposure of donors to
infectious diseases and vaccinations, IVIg
contains antibodies to a wide range of
infectious agents, and hence these anti-
microbial antibodies within IVIg prepa-
rations can directly neutralize pathogens
[53]. However, determining an effective
dose regimen and duration of IVIg
therapy needs further investigation.
In our opinion, considering all thera-
peutic options, a ‘‘triple’’ combination of
anti-microbial agents, B cell–targeted
therapies, and IVIg represents the most
appropriate and ideal method for treating
autoimmunity-associated infectious diseas-
es. Indeed, the combination of B cell–
targeted therapies and IVIg has been
successfully used in several autoimmune
and inflammatory diseases [54,55].
Accession Numbers/ID Numbers
for Genes and Proteins:
UniProtKB
The UniProt (http://www.uniprot.org/)
accession numbers for genes and proteins
discussed in this paper are IL-17A,
Q16552; IL-17F, Q96PD4; IL-21,
Q9HBE4; IL-22, Q9GZX6; IL-23,
Q9NPF7; IL-12RB2, Q99665; IFN-c,
P01579; GM-CSF, P01587; IL-6, P05231;
IL-4, P05112; IL-5, P05113; IL-13,
P35225; BAFF (BLyS), Q9Y275; IFN-a2,
P01563; IFN-v, P05000; TNF-a, P01375;
IL-1b, P01584; IL-12 p40 (IL-12B),
P29460; IL-12 p35 (IL-12A), P29459;
AIRE, O43918; STAT3, P40763; HLA-
DR, O19685; CD20, P11836; CD11b,
P11215; CD19, P15391; CD22, P20273.
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